{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:22:06Z","timestamp":1777983726367,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003718","name":"Korea Institute of Oriental Medicine","doi-asserted-by":"publisher","award":["KSN2412013"],"award-info":[{"award-number":["KSN2412013"]}],"id":[{"id":"10.13039\/501100003718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003718","name":"Korea Institute of Oriental Medicine","doi-asserted-by":"publisher","award":["KSN2412013"],"award-info":[{"award-number":["KSN2412013"]}],"id":[{"id":"10.13039\/501100003718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2022R1A2C2092834"],"award-info":[{"award-number":["NRF-2022R1A2C2092834"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"DOI":"10.1038\/s41389-026-00607-3","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:50:24Z","timestamp":1773823824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Teriflunomide modulates the PD-1\/PD-L1 axis and enhances antitumor immunity in colorectal cancer"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8471-6513","authenticated-orcid":false,"given":"Jung Ho","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Ji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Hye","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazi Rejvee","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jang-Gi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5901-0217","authenticated-orcid":false,"given":"Hwan-Suck","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"607_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"S-R Woo","year":"2012","unstructured":"Woo S-R, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72:917\u201327.","journal-title":"Cancer Res"},{"key":"607_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","volume":"43","author":"F Petrelli","year":"2020","unstructured":"Petrelli F, Grizzi G, Ghidini M, Ghidini A, Ratti M, Panni S, et al. Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Immunother. 2020;43:1\u20137.","journal-title":"J Immunother"},{"key":"607_CR3","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","volume":"26","author":"T Chen","year":"2015","unstructured":"Chen T, Razak A, Bedard P, Siu L, Hansen A. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol. 2015;26:1824\u20139.","journal-title":"Ann Oncol"},{"key":"607_CR4","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","volume":"56","author":"S Agarwal","year":"2023","unstructured":"Agarwal S, Aznar MA, Rech AJ, Good CR, Kuramitsu S, Da T, et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity. 2023;56:2388\u2013407.e9.","journal-title":"Immunity"},{"key":"607_CR5","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","volume":"20","author":"LP Andrews","year":"2019","unstructured":"Andrews LP, Yano H, Vignali DA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20:1425\u201334.","journal-title":"Nat Immunol"},{"key":"607_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39:98\u2013106.","journal-title":"Am J Clin Oncol"},{"key":"607_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38:473\u201388.","journal-title":"Cancer Cell"},{"key":"607_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153723","volume":"229","author":"S Taefehshokr","year":"2022","unstructured":"Taefehshokr S, Parhizkar A, Hayati S, Mousapour M, Mahmoudpour A, Eleid L, et al. Cancer immunotherapy: challenges and limitations. Pathol Res Pract. 2022;229:153723.","journal-title":"Pathol Res Pract"},{"key":"607_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118:9\u201316.","journal-title":"Br J Cancer"},{"key":"607_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.alit.2022.01.001","volume":"71","author":"N Okiyama","year":"2022","unstructured":"Okiyama N, Tanaka R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergol Int. 2022;71:169\u201378.","journal-title":"Allergol Int"},{"key":"607_CR11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/bjh.15644","volume":"183","author":"KA Hay","year":"2018","unstructured":"Hay KA. Cytokine release syndrome and neurotoxicity after CD 19 chimeric antigen receptor-modified (CAR-) T cell therapy. Br J Haematol. 2018;183:364\u201374.","journal-title":"Br J Haematol"},{"key":"607_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","volume":"64","author":"S Khan","year":"2020","unstructured":"Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin Cancer Biol. 2020;64:93\u2013101.","journal-title":"Semin Cancer Biol"},{"key":"607_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/PPA.S61651","volume":"9","author":"A Bayas","year":"2015","unstructured":"Bayas A, M\u201eurer M. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherence. Patient Prefer Adher. 2015;9:265\u201374.","journal-title":"Patient Prefer Adher"},{"key":"607_CR14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/ard.59.11.841","volume":"59","author":"F Breedveld","year":"2000","unstructured":"Breedveld F, Dayer J. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2000;59:841\u20139.","journal-title":"Ann Rheum Dis"},{"key":"607_CR15","doi-asserted-by":"publisher","first-page":"874","DOI":"10.2174\/1570159X14666161208151525","volume":"15","author":"L Aly","year":"2017","unstructured":"Aly L, Hemmer B, Korn T. From leflunomide to teriflunomide: drug development and immunosuppressive oral drugs in the treatment of multiple sclerosis. Curr Neuropharmacol. 2017;15:874\u201391.","journal-title":"Curr Neuropharmacol"},{"key":"607_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3109\/03639045.2015.1044906","volume":"42","author":"J Bae","year":"2016","unstructured":"Bae J, Park JW. Topical delivery of leflunomide for rheumatoid arthritis treatment: Evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model. Drug Dev Ind Pharm. 2016;42:254\u201362.","journal-title":"Drug Dev Ind Pharm"},{"key":"607_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211035542","volume":"14","author":"T Brummer","year":"2021","unstructured":"Brummer T, Ruck T, Meuth SG, Zipp F, Bittner S. Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders. Ther Adv Neurol Disord. 2021;14:17562864211035542.","journal-title":"Ther Adv Neurol Disord"},{"key":"607_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40170-021-00250-z","volume":"9","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Tao L, Zhou X, Zuo Z, Gong J, Liu X, et al. DHODH and cancer: promising prospects to be explored. Cancer Metab. 2021;9:22.","journal-title":"Cancer Metab"},{"key":"607_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29\u201339.","journal-title":"Int Immunopharmacol"},{"key":"607_CR20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fcell.2020.00672","volume":"8","author":"Q Lei","year":"2020","unstructured":"Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors. Front Cell Dev Biol. 2020;8:672.","journal-title":"Front Cell Dev Biol"},{"key":"607_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.554313","volume":"10","author":"C Su","year":"2020","unstructured":"Su C, Wang H, Liu Y, Guo Q, Zhang L, Li J, et al. Adverse effects of anti-PD-1\/PD-L1 therapy in non-small cell lung cancer. Front Oncol. 2020;10:554313.","journal-title":"Front Oncol"},{"key":"607_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/imm.13785","volume":"173","author":"L Cai","year":"2024","unstructured":"Cai L, Chen A, Tang D. A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: Multi-pathway combination therapy with PD-1\/PD-L1 inhibitors. Immunology. 2024;173:209\u201326.","journal-title":"Immunology"},{"key":"607_CR23","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/bjc.2015.101","volume":"112","author":"K Abiko","year":"2015","unstructured":"Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, et al. IFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112:1501\u20139.","journal-title":"Br J Cancer"},{"key":"607_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","volume":"54","author":"C Blank","year":"2005","unstructured":"Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54:307\u201314.","journal-title":"Cancer Immunol Immunother"},{"key":"607_CR25","doi-asserted-by":"publisher","first-page":"e004695","DOI":"10.1136\/jitc-2022-004695","volume":"10","author":"RC Ac\u00a3rcio","year":"2022","unstructured":"Ac\u00a3rcio RC, Pozzi S, Carreira B, Pojo M, G\u00f3mez-Cebri\u00e1n N, Casimiro S. Therapeutic targeting of PD-1\/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment. J ImmunoTher Cancer. 2022;10:e004695","journal-title":"J ImmunoTher Cancer"},{"key":"607_CR26","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3324\/haematol.2012.077537","volume":"98","author":"D Brusa","year":"2013","unstructured":"Brusa D, Serra S, Coscia M, Rossi D, D\u2019Arena G, Laurenti L, et al. The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013;98:953.","journal-title":"Haematologica"},{"key":"607_CR27","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nri1632","volume":"5","author":"F Macian","year":"2005","unstructured":"Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005;5:472\u201384.","journal-title":"Nat Rev Immunol"},{"key":"607_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Christensen JP, G\u00f6genur I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124:359\u201367.","journal-title":"Br J Cancer"},{"key":"607_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103663","volume":"173","author":"AE Boukouris","year":"2022","unstructured":"Boukouris AE, Theochari M, Stefanou D, Papalambros A, Felekouras E, Gogas H, et al. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. Crit Rev Oncol\/Hematol. 2022;173:103663.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"607_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0738-1","volume":"12","author":"P Zhao","year":"2019","unstructured":"Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12:1\u201314.","journal-title":"J Hematol Oncol"},{"key":"607_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.108962","volume":"237","author":"L Chen","year":"2022","unstructured":"Chen L, Jiang X, Li Y, Zhang Q, Li Q, Zhang X, et al. How to overcome tumor resistance to anti-PD-1\/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC. Clin Immunol. 2022;237:108962.","journal-title":"Clin Immunol"},{"key":"607_CR32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fimmu.2020.00369","volume":"11","author":"E Picard","year":"2020","unstructured":"Picard E, Verschoor CP, Ma GW, Pawelec G. Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Front Immunol. 2020;11:369.","journal-title":"Front Immunol"},{"key":"607_CR33","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.","journal-title":"Front Pharmacol"},{"key":"607_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-020-00212-5","volume":"8","author":"J-Y Sun","year":"2020","unstructured":"Sun J-Y, Zhang D, Wu S, Xu M, Zhou X, Lu X-J, et al. Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark Res. 2020;8:1\u201310.","journal-title":"Biomark Res"},{"key":"607_CR35","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/s12276-023-01078-x","volume":"55","author":"W Park","year":"2023","unstructured":"Park W, Wei S, Kim B-S, Kim B, Bae S-J, Chae YC, et al. Diversity and complexity of cell death: a historical review. Exp Mol Med. 2023;55:1573\u201394.","journal-title":"Exp Mol Med"},{"key":"607_CR36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20:326\u201336.","journal-title":"Nat Immunol"},{"key":"607_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023;23:90\u2013105.","journal-title":"Nat Rev Immunol"},{"key":"607_CR38","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression\u2014implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16:356\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"607_CR39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","volume":"21","author":"KC Ohaegbulam","year":"2015","unstructured":"Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21:24\u201333.","journal-title":"Trends Mol Med"},{"key":"607_CR40","first-page":"15","volume":"2","author":"E Nwankwo","year":"2012","unstructured":"Nwankwo E, Allington DR, Rivey MP. Emerging oral immunomodulating agents-focus on teriflunomide for the treatment of multiple sclerosis. Degener Neurol Neuromusc Dis. 2012;2:15\u201328.","journal-title":"Degener Neurol Neuromusc Dis"},{"key":"607_CR41","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.3390\/nu16244415","volume":"16","author":"A Kim","year":"2024","unstructured":"Kim A, Lee E-J, Han JH, Chung H-S. Caryophylli cortex suppress PD-L1 expression in cancer cells and potentiates anti-tumor immunity in a humanized PD-1\/PD-L1 knock-in MC-38 colon cancer mouse model. Nutrients. 2024;16:4415.","journal-title":"Nutrients"},{"key":"607_CR42","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2016.04.011","volume":"21","author":"M-M Zhan","year":"2016","unstructured":"Zhan M-M, Hu X-Q, Liu X-X, Ruan B-F, Xu J, Liao C. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1\/PD-L1 pathway. Drug Discov Today. 2016;21:1027\u201336.","journal-title":"Drug Discov Today"},{"key":"607_CR43","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1177\/1352458512436594","volume":"18","author":"C Confavreux","year":"2012","unstructured":"Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler J. 2012;18:1278\u201389.","journal-title":"Mult Scler J"},{"key":"607_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41401-020-0366-x","volume":"42","author":"Q Wu","year":"2021","unstructured":"Wu Q, Jiang L, Li S-c, He Q-j, Yang B, Cao J. Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway. Acta Pharmacol Sin. 2021;42:1\u20139.","journal-title":"Acta Pharmacol Sin"},{"key":"607_CR45","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1080\/14740338.2017.1388371","volume":"16","author":"F Auricchio","year":"2017","unstructured":"Auricchio F, Scavone C, Cimmaruta D, Di Mauro G, Capuano A, Sportiello L, et al. Drugs approved for the treatment of multiple sclerosis: review of their safety profile. Expert Opin Drug Saf. 2017;16:1359\u201371.","journal-title":"Expert Opin Drug Saf"},{"key":"607_CR46","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/978-1-0716-3441-7_6","volume":"2714","author":"Y Liu","year":"2023","unstructured":"Liu Y, Cao Y. Protein-ligand blind docking using CB-Dock2. Methods Mol Biol. 2023;2714:113\u201325.","journal-title":"Methods Mol Biol"},{"key":"607_CR47","doi-asserted-by":"publisher","first-page":"W387","DOI":"10.1093\/nar\/gks336","volume":"40","author":"DR Koes","year":"2012","unstructured":"Koes DR, Camacho CJ. PocketQuery: protein\u2013protein interaction inhibitor starting points from protein\u2013protein interaction structure. Nucleic Acids Res. 2012;40:W387\u2013W92.","journal-title":"Nucleic Acids Res"},{"key":"607_CR48","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/1535370214554881","volume":"240","author":"O Huang","year":"2015","unstructured":"Huang O, Zhang W, Zhi Q, Xue X, Liu H, Shen D, et al. Featured Article: Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells. Exp Biol Med. 2015;240:426\u201337.","journal-title":"Exp Biol Med"}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00607-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00607-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00607-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:02:23Z","timestamp":1773910943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00607-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["607"],"URL":"https:\/\/doi.org\/10.1038\/s41389-026-00607-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7590655\/v1","asserted-by":"object"}]},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were performed in accordance with the relevant guidelines and regulations. The study was approved by the Institutional Animal Care and Use Committee (IACUC) of the Korea Institute of Oriental Medicine (KIOM) (approval number: KIOM-D-23-099).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"15"}}